Comparative Pharmacology
Head-to-head clinical analysis: PEXEVA versus ZOLOFT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEXEVA versus ZOLOFT.
PEXEVA vs ZOLOFT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).
50 mg orally once daily, increased by 50 mg increments at 1-week intervals up to 200 mg/day for depression, OCD, panic disorder, PTSD, PMDD, social anxiety disorder.
None Documented
None Documented
60-120 hours (chronic dosing); steady-state achieved in 4-5 weeks
26 hours (terminal elimination half-life); steady state achieved in ~1 week; metabolite desmethylsertraline half-life 66 hours.
Primarily renal (70% as metabolites, 2% unchanged); fecal (27%)
Renal: <0.5% unchanged; extensive hepatic metabolism; metabolites excreted renally and fecally.
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant